Meijer, E.

patient lenalidomide reactivation graft cmv infection cycle donor blood cell transplantation allo-sct infection transplantation maintenance cmv-positive treatment recipient fi rst cycle grade disease myeloma study lenalidomide maintenance month response allogeneic cmv-positive graft erasmus mc cmv-negative trial cmv-negative graft analysis criteria figure therapy range frequency transplant number nma allo-sct center cmv-speci signi utrecht marrow effect incidence 1 patient result center utrecht status regimen group autologou erasmu 24 cycles cytomegaloviru terminology criteria development serostatu table article induction research university progression hematology unmanipulated graft autologous sct immunity day 15 strain value 2012. cmv-positive donor lenalidomide treatment netherland 6 months cmv-positive recipients nonmyeloablative cmv serostatus